entertainment -WSS

entertainment

author：explore 2025-09-14 21:35:54 - browse：68

A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT — Jonathan Wiggs /Globe Staff

Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： STAT Summit: Michael J. Fox on progress in Parkinson's research

WSS

Group opposing PBM reform sets lobbying record

Google and Epic fight stronger regulation of AI in health care

Why health workers in Gaza are injured or die at high rates

Startup Neumora takes a novel depression drug to Phase 3

2023 STAT Wunderkinds: get to know the winners

First Opinion Podcast: Long Covid needs a new approach

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

Group opposing PBM reform sets lobbying record

Cancer drug shortages should be causing more outrage

HHS leader on health, climate change and biopharma emissions

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Novavax promises a turnaround & Lilly roils the obesity market

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Listen: Wegovy in the brain & pivotal Alzheimer's data

hotspot

As digital health tech proliferates, a new institute aims to cut through hype

Solve the antibiotic resistance crisis with preventive drugs

FDA approves RSV monoclonal antibody for infants, toddlers

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Group opposing PBM reform sets lobbying record

STAT Readout Newsletter: Today's biggest biotech updates

hotspot

explore

hotspot

focus